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CIB1 protects against MPTP-
induced neurotoxicity through 
inhibiting ASK1
Kyoung Wan Yoon1,2, Hyun-Suk Yang2, Young Mok Kim1, Yeonsil Kim1, Seongman Kang1, 
Woong Sun  3, Ulhas P. Naik4, Leslie V. Parise5 & Eui-Ju Choi1
Calcium and integrin binding protein 1 (CIB1) is a calcium-binding protein that was initially identified 
as a binding partner of platelet integrin αIIb. Although CIB1 has been shown to interact with multiple 
proteins, its biological function in the brain remains unclear. Here, we show that CIB1 negatively 
regulates degeneration of dopaminergic neurons in a mouse model of Parkinson’s disease using 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Genetic deficiency of the CIB1 gene enhances 
MPTP-induced neurotoxicity in dopaminergic neurons in CIB1−/− mice. Furthermore, RNAi-mediated 
depletion of CIB1 in primary dopaminergic neurons potentiated 1-methyl-4-phenyl pyrinidium (MPP+)-
induced neuronal death. CIB1 physically associated with apoptosis signal-regulating kinase 1 (ASK1) 
and thereby inhibited the MPP+-induced stimulation of the ASK1-mediated signaling cascade. These 
findings suggest that CIB1 plays a protective role in MPTP/MPP+-induced neurotoxicity by blocking 
ASK1-mediated signaling.
Parkinson’s disease is a neurodegenerative disease characterized by the selective loss of dopaminergic neurons 
in the substantia nigra pars compacta (SNpc) and their targets in the striatum1–3. Although the molecular mech-
anism underlying the loss of SNpc neurons is not clearly understood, mitochondrial dysfunction with a defect 
of complex I appears to be one of the key features in the pathogenesis of Parkinson’s disease2,4. Dysfunction of 
complex I results in enhanced production of reactive oxygen species (ROS), thereby causing oxidative stress5. 
Massive ROS generation induces cell death signaling pathways, including stress-activated protein kinase path-
ways such as the c-Jun NH2-terminal kinase (JNK) pathway. JNK activation in dopaminergic neurons has been 
shown in animal models of Parkinson’s disease as well as in human patients6,7. Furthermore, a JNK inhibitor 
exhibits a neuroprotective effect in animal models of the disease8,9. Apoptosis signal-regulating kinase 1 (ASK1), a 
mitogen-activated protein kinase kinase kinase (MAP3K) in the JNK pathway, is also activated in a mouse model 
of Parkinson’s disease and mediates cell death of dopaminergic neurons10,11.
CIB1 is a calcium-binding protein of 22 kDa, containing two canonical EF-hand domains in the 
carboxyl-terminal globular region12,13. CIB1, which was originally identified as a calcium and integrin binding 
protein14, appears to be involved in the regulation of various physiological and pathological processes includ-
ing spermatogenesis15, ischemia-induced angiogenesis16, and cardiac hypertrophy17. CIB1 interacts with a num-
ber of proteins, including Rac3 and several serine/threonine kinases such as polo-like kinases, focal adhesion 
kinase, and p21-activated kinase18–21. It also physically associates with and inhibits ASK1, thereby preventing 
stress-induced apoptosis in a calcium ion-sensitive manner22. CIB1 is ubiquitously expressed in various cell types 
including neurons in the brain14,19,23,24. In particular, CIB1 in the brain has been reported to be involved in micro-
tubule dynamics during neurite outgrowth25, synaptic plasticity through interacting with the polo-like kinases 
Fnk and Snk in hippocampal neurons19, and neuronal development with targeting NBR1 and FEZ1 in neural 
tube26. However, its biological function in the neuronal system remains unclear.
We previously showed that CIB1 negatively regulates the stress-induced apoptosis of cultured dopaminergic 
neurons22. In order to better understand a regulatory function of CIB1 in the pathogenesis of Parkinson’s disease, 
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we have now investigated the inhibitory action of CIB1 against dopaminergic neurotoxicity in a mouse model 
of the disease using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP is a neurotoxin that causes 
Parkinson’s disease in humans and vertebrates that is clinically almost indistinguishable from sporadic Parkinson’s 
disease27. Here, we show that ablation of the CIB1 gene in mice increased the susceptibility of dopaminergic 
neurons to MPTP toxicity. Moreover, CIB1 inhibited the stimulation of ASK1 activity induced by 1-Methyl-
4-phenylpyridinium (MPP+), the toxic metabolite of MPTP. Collectively, our findings suggest that CIB1 mitigates 
MPTP/MPP+-induced neurotoxicity by targeting ASK1.
Results
Genetic ablation of CIB1 in mice potentiates MPTP-induced dopaminergic neurotoxicity. CIB1 
was previously shown to reduce dopaminergic neuronal death induced by 6-hydroxydopamine, a widely used 
neurotoxin in experimental models of Parkinson’s disease22. To better understand the in vivo function of CIB1 
in the pathogenesis of Parkinson’s disease, we examined the effect of CIB1 gene deletion on loss of dopamin-
ergic neurons in the SNpc in a MPTP mouse model of the disease. Immunohistochemical staining for tyros-
ine hydroxylase (TH) and stereological analysis revealed that MPTP treatment resulted in a more severe loss of 
TH-positive dopaminergic neurons in the SNpc of CIB1-knockout (CIB1−/−) mice, compared to that of wild-type 
mice (Fig. 1A,B). Furthermore, MPTP administration reduced the TH-positive fibers in the striatum in wild-type 
mice, and this reduction was further aggravated by ablation of the CIB1 gene in CIB1−/− mice (Fig. 1C).
CIB1 depletion by RNA interference potentiates MPP+-induced dopaminergic neuronal 
death. Monoamine oxidase B (MAO-B) in the brain converts MPTP to a toxic metabolite, MPP+. MPP+ 
causes mitochondrial dysfunction by inhibiting complex I of the electron transport chain, leading to oxidative 
stress-induced cell death28,29. In our initial experiments, we examined the effect of CIB1 on MPP+-induced 
Figure 1. CIB1 deficiency potentiates MPTP-induced loss of dopaminergic neurons. (A) Wild-type (WT) and 
CIB1−/− mice (2~3-month-old group) were treated with MPTP (30 mg/kg every 24 h, five times) or saline by 
intraperitoneal injection. Immunohistochemical staining for TH was performed on coronal brain sections from 
WT and CIB1−/− mice. Numbers of TH-positive neurons in the substantia nigra pars compacta were analyzed 
by stereological counting. Data are means ± SD (n = 5). *P < 0.05. (B,C) The representative images of TH-
stained neurons in substantia nigra pars compacta (B) or striatum (C) of WT and CIB1−/−mice were shown. 
Scale bars, 100 μm (B) and 250 μm (C).
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apoptotic cell death in human neuroblastoma SH-SY5Y cells. MPP+ increased apoptotic cell death in these cells, 
and this effect was further enhanced by RNA interference (RNAi)-mediated depletion of CIB1 (Fig. 2A, Fig. S1A). 
Furthermore, forced expression of CIB1 in SH-SY5Y cells reduced the MPP+-induced apoptosis (Fig. S2). Next, 
we examined the effect of CIB1 on MPP+-induced neurotoxicity in a primary culture of rat mesencephalic dopa-
minergic neurons. Immunocytochemical analysis of TH-positive neurons revealed that MPP+ reduced viability 
of mesencephalic dopaminergic neurons, and this toxic effect was further potentiated by siRNA-mediated deple-
tion of CIB1 (Fig. 2B, Fig. S1B). Together, these results suggest that CIB1 mitigates MPP+-induced neurotoxicity 
in dopaminergic neurons.
CIB1 negatively regulates the ASK1-JNK signaling pathway. MPP+ treatment enhances ROS pro-
duction, which is critical for MPP+-induced apoptosis30,31. Therefore, we examined whether CIB1 could modulate 
MPP+-induced ROS generation. As expected, MPP+ treatment resulted in an increase in ROS production in 
SH-SY5Y cells, and this increase was not changed by RNAi-mediated depletion of CIB1 expression in these cells 
(Fig. S3). These results suggest that CIB1 does not affect MPP+-induced ROS production.
CIB1 has been shown to inhibit ASK1-dependent signaling events22. Given that ASK1 mediates 
MPP+-induced neuronal death and MPTP-induced Parkinsonism6,10,32,33, we investigated whether CIB1 could 
regulate MPP+-induced ASK1 signaling. MPP+ treatment induced the stimulation of ASK1 in rat primary mes-
encephalic dopaminergic neurons, and this stimulation was potentiated by siRNA-mediated depletion of CIB1 
expression in these cells (Fig. 3A). Thus, these results indicated that CIB1 negatively regulates the MPP+-induced 
Figure 2. CIB1 mitigates MPP+-induced neurotoxicity in dopaminergic neurons. (A) SH-SY5Y cells expressing 
either control (GFP) or CIB1 shRNA were incubated for 20 h in the absence or presence of 3 mM MPP+. Then, 
the cells were stained with red fluorescein (TMR red)-labeled TUNEL and analyzed by flow cytometry. The 
apoptosis was determined by TUNEL-positive population showing positively shifted TMR red signal. The 
percents of TUNEL-positive cells are indicated as apoptotic population. Representative data of apoptosis are 
shown in the right panel. The left graph represents mean ± SD calculated from triplicate experiments (n = 3). 
*P < 0.05. (B) Primary mesencephalic neurons in culture were transfected for 48 h with control (GFP) or 
CIB1 siRNA. The neurons were left untreated or treated with 200 μM MPP+ for 20 h, and then were subjected 
to immunocytochemistry with anti-TH antibody. The representative images of the stained cells are shown 
in the right panels (scale bar, 100 μm), and the viability of TH-positive neurons is shown in the left panel as 
a percentage of that for control siRNA-transfected untreated cells. Data are means ± SD of values from three 
independent experiments. *P < 0.05.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 12178  | DOI:10.1038/s41598-017-12379-3
stimulation of ASK1. Furthermore, forced expression of CIB1 inhibited the ASK1-induced activation of JNK in 
SH-SY5Y cells transfected with vectors for Flag-CIB1, HA-ASK1, and Myc-JNK1 (Fig. 3B), suggesting that CIB1 
inhibits the ASK1-induced stimulation of JNK1.
CIB1 physically interacts with ASK1. CIB1 interacts with ASK122. Indeed, in vitro binding assay data 
revealed that glutathione S-transferase (GST)-fused CIB1 physically associated with a deletion mutant of ASK1 
consisting of amino acids 378 to 648 [ASK1 (378-648)] (Fig. 4A). ASK1 (378–648) contains the amino-terminal 
regulatory domain34, which is also responsible for the binding of ASK1 to TRAF235. Next, we examined whether 
MPP+ could modulate the interaction between CIB1 and ASK1. Co-immunoprecipitation analysis data indicated 
that CIB1 interacted with ASK1 in primary mesencephalic neurons (Fig. 4B), and that this interaction was not 
affected by MPP+ treatment.
CIB1 blocks the binding of TRAF2 to ASK1 and the phosphorylation of ASK1 on Thr845. ASK1 
in a basal state appears to form a complex with the reduced form of the redox protein thioredoxin-1 (Trx1), 
which keeps ASK1 inactive36. When oxidative stress enhances cellular ROS generation, Trx1 is oxidized and 
dissociates from ASK1. Subsequently, TRAF2 is recruited to free ASK1 and promotes the autophosphorylation of 
ASK1 at a threonine residue in the catalytic domain (Thr838 or Thr845 in the human or mouse ASK1, respectively), 
Figure 3. CIB1 inhibits the MPP+-induced stimulation of ASK1 in primary dopaminergic neurons. (A) 
Primary mesencephalic neurons were transfected for 48 h with either control (GFP) or CIB1 siRNA. The 
neurons were incubated in the absence or presence of 200 μM MPP+ for 2 h. Cell lysates were subjected to 
immunoprecipitation with anti-ASK1 antibody. The resulting precipitates were assayed for ASK1 activity 
using substrates GST-MKK6 (K82A). The lysates were also examined directly by immunoblot analysis with 
antibodies to CIB1 or ASK1. (B) SH-SY5Y cells were transfected for 48 h with the indicated combinations 
of expression vectors for HA-ASK1, Flag-CIB1, and Myc-JNK1. The cells were then lysed and subjected to 
immunoprecipitation with anti-Myc antibody, and the resulting precipitates were assayed for JNK1 activity.
Figure 4. CIB1 physically associates with ASK1 in mesencephalic dopaminergic neurons. (A) A schematic 
representation of ASK1 indicating the thioredoxin-binding region (gray box), the TRAF2-binding region 
(dotted box), and the kinase domain (hatched box) is shown in the upper panel. The indicated 35S-labled ASK1 
variants were produced by in vitro translation and incubated for 4 h at 4 °C with GST-CIB1 immobilized on 
glutathione-agarose beads. The bead-bound 35S-labled proteins were eluted and detected by SDS-PAGE and 
autoradiography. The gel was also stained with Coomassie Brilliant Blue. A portion (25%) of the 35S-labled 
protein input to the binding reaction was also directly subjected to SDS-PAGE and autoradiography. (B) 
Primary mesencephalic neurons in culture were incubated in the absence or presence of 200 μM MPP+ for 2 h, 
lysed, and subjected to immunoprecipitation (IP) with antibodies to ASK1 (α-ASK1) or with rabbit preimmune 
IgG (control). The resulting precipitates as well as cell lysates were subjected to immunoblot (IB) analysis with 
antibodies to CIB1 or to ASK1.
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resulting in ASK1 activation36–38. In order to understand the mechanism by which CIB1 inhibits ASK1 activa-
tion, we examined whether CIB1 could affect the interaction between ASK1 and Trx1. Co-immunoprecipitation 
analysis revealed that CIB1 did not change the interaction between Trx1 and ASK1 (Fig. 5A). Next, we tested 
whether CIB1 could affect the MPP+-induced binding of ASK1 to TRAF2 in primary mesencephalic neurons. 
MPP+ induced the interaction between ASK1 and TRAF2 in the neurons, which was further enhanced by 
CIB1 depletion (Fig. 5B). These results suggest that CIB1 negatively regulates MPP+-induced recruitment of 
TRAF2 to ASK1. It is noteworthy that the CIB1-binding region of ASK1 as shown in Fig. 4A overlaps with the 
TRAF2-binding region of the kinase35. Next, we examined the effect of CIB1 on the MPP+-induced phosphoryl-
ation of ASK1 at Thr845. MPP+ treatment increased ASK1(Thr845) phosphorylation in primary mesencephalic 
neurons, and this increase was further enhanced by CIB1 depletion (Fig. 5C). We also examined the action of 
CIB1 on the MPP+-induced interaction between ASK1 and MKK7. MKK7 is a mitogen-activated protein kinase 
kinase (MAP2K), acting as the downstream kinase of ASK1, in the JNK pathway39,40. Our results revealed that 
depletion of CIB1 enhanced the interaction between ASK1 and MKK7 in CIB1 siRNA-transfected cells (Fig. 5D), 
suggesting that CIB1 negatively regulates the binding of ASK1 to its substrate MKK7. Consistent with these 
results, ectopically expressed CIB1 inhibited the interaction between ASK1 and MKK7 in transfected SH-SY5Y 
cells (Fig. S4). Together, our results suggest that CIB1 inhibits the stimulating effect of MPP+ on the recruitment 
of TRAF2 to ASK1, ASK1(Thr845) phosphorylation, and the binding of ASK1 to its substrate, MKK7, in primary 
mesencephalic neurons. Of note, the abundance of TRAF2, ASK1, and MKK7 in the SNpc of the mouse brain was 
not affected by either MPTP treatment or the deletion of CIB1 gene (Fig. S5).
Depletion of ASK1 expression by RNAi abolishes the protective effect of CIB1 against 
MPP+-induced neurotoxicity. Given that CIB1 directly binds ASK1 and thereby inhibits the 
MPP+-induced activation processes of ASK1, we reasoned that the blockade of ASK1 by CIB1 may be an 
important part of the mechanism by which CIB1 negatively regulates MPP+-mediated toxicity in dopaminer-
gic neurons. If its inhibition of ASK1 is crucial for the neuroprotective function of CIB1, it would be expected 
Figure 5. CIB1 inhibits the binding of TRAF2 to ASK1 and the phosphorylation of ASK1 on Thr845 in intact 
cells. (A) SH-SY5Y cells were transfected for 48 h with the indicated combinations of vectors encoding Flag-
CIB1, HA-Trx1, and Myc-ASK1. Cell lysates were subjected to immunoprecipitation with anti-HA antibody. 
The resulting precipitates were subjected to immunoblot analysis with anti-Myc antibody. Cell lysates were 
also examined directly by immunoblot analysis with the indicated antibodies. (B,C,D) Primary mesencephalic 
neurons in culture were transfected with either control or CIB1 siRNA for 48 h. The neurons were left untreated 
or treated with 200 μM MPP+ for 2 h, lysed, and subjected to immunoprecipitation with antibody to ASK1 
(B,C) or antibody to MKK7 (D). The resulting precipitates were immunoblotted with antibodies to ASK1. Cell 
lysates were also immunoblotted directly with antibodies to CIB1, to ASK1, or to MKK7. The levels of protein 
expression are determined by relative fold of band image intensity (the first lane, fold 1.0).
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that depletion of ASK1 expression in cells might abolish the protective effect of CIB1. We, therefore, examined 
this possibility with using primary culture of dopaminergic neurons. MPP+ treatment reduced cell viability of 
primary dopaminergic neurons prepared from wild type mouse brain and this neurotoxic effect of MPP+ was 
further aggravated by ablation of CIB1 gene in CIB1−/− dopaminergic neurons (Fig. 6), suggesting that CIB1 
negatively regulates MPP+-induced death of dopaminergic neurons. Interestingly, the aggravating effect of CIB1 
gene ablation on the MPP+-induced neurotoxicity was abolished by siRNA-mediated ASK1 depletion in the 
CIB1−/− neurons.
Discussion
MPTP is widely used as a neurotoxin in an experimental model of Parkinson’s disease41. It produces neuropatho-
logical events similar to those observed in Parkinson’s disease patients, including progressive loss of dopamin-
ergic neurons in the SNpc and reduction of striatal dopamine levels42. The neurotoxic effect of MPTP depends 
on the transformation of MPTP to its bioactive form MPP+ by monoamine oxidase B in glial cells. MPP+ can 
be taken up into dopaminergic neurons by their dopamine transporters. MPP+ inhibits mitochondrial complex 
I, resulting in decreased production of ATP, increased generation of ROS, and apoptosis43–45. The ASK1-JNK1 
signaling cascade has been shown to mediate MPTP/MPP+-induced neurotoxicity6,11. In line with this notion, in 
the present study, RNAi-mediated ASK1 depletion nullified the MPP+-induced death of dopaminergic neurons 
(Fig. 6), revealing a crucial role of ASK1 in MPTP/MPP+ neurotoxicity.
CIB1 is expressed ubiquitously in many cell types and has multiple binding partners, implying its diverse role 
in a variety of biological events including calcium signaling, proliferation, survival, migration, and adhesion46. 
However, the physiological and pathological functions of CIB1 are not completely understood. Interestingly, pub-
lic gene expression profiling data indicate that CIB1 is highly expressed in various regions of the brain, including 
SNpc47, implicating its potentially important role in the brain. Noticeably, CIB1 exerts its anti-apoptotic function 
in neurons by blocking the ASK1-JNK pathway22.
In this study, we observed that a genetic deficiency of the CIB1 gene enhances MPTP-induced apoptosis in 
dopaminergic neurons as well as destruction of the nigral-striatal projections in CIB1−/− mice (Fig. 1), suggesting 
Figure 6. siRNA-mediated depletion of ASK1 abolishes the protective effect of CIB1 on MPP+-initiated 
neurotoxicity. Primary mesencephalic neurons in culture prepared from WT or CIB−/− mice were transfected 
for 48 h with control (GFP) or ASK1 siRNA. The neurons were left untreated or treated with 200 μM MPP+ 
for 20 h, and then were subjected to immunostaining with anti-TH antibody. The representative images of the 
stained cells are shown in the bottom panels (scale bar, 100 μm), and the viability of TH-positive neurons is 
shown in the top panel as a percentage of that of control siRNA-transfected untreated cells. Data are means ± SD 
of values from three independent experiments. *P < 0.05.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 12178  | DOI:10.1038/s41598-017-12379-3
a protective action of CIB1 against MPTP-induced dopaminergic neurotoxicity. MPTP has been shown to induce 
microglial activation48,49, and chronic microglial activation and inflammation affect the progression of Parkinson’s 
disease50. However, we have ruled out a possibility that the neuroprotective action of CIB1 might result from its 
modulation of the activation of microglia and astrocytes, because CIB1 was hardly detected in either microglia or 
astrocytes in the SNpc of mouse brain (Fig. S6A). Additionally, CIB1 does not affect the MPP+-induced expres-
sion of inflammation-linked cytokines including TNFα and interleukin-6 in microglial BV-2 cells (Fig. S6B). 
Instead, CIB1 physically associates with ASK1, and thereby prevents ASK1 activation induced by MPP+. CIB1 
binds to the region containing amino acid residues 378–648 of ASK1 (Fig. 4A). Intriguingly, the CIB1-interacting 
region of ASK1 is also important for its binding to TRAF235,37. Thus, CIB1 and TRAF2 may compete with each 
other for an overlapping binding region on ASK1. By binding to ASK1, CIB1 may prevent the recruitment of 
TRAF2 and subsequent steps of ASK1 activation including the Thr845 phosphorylation of ASK1. Moreover, 
depletion of ASK1 expression by RNAi abolishes the inhibitory action of CIB1 on MPP+-induced neurotox-
icity (Fig. 6). Together, our results suggest that the inhibition of ASK1 by CIB1 may be the primary mechanism 
underlying the protective effect of CIB1 against MPTP/MPP+-induced neurotoxicity. Interestingly, either the 
expression levels of CIB1 or its binding to ASK1 in dopaminergic neurons was not changed by MPP+ treatment 
(Figs 3 and 4). These results imply that a portion of ASK1, which forms a complex with CIB1, is unresponsive 
to MPTP/MPP+-induced stress and is kept inactive even under the stress. In this way, CIB1 may prevent the 
hyper-activation of ASK1 and neurotoxicity during exposure of neurons to MPTP/MPP+. Thus, CIB1 may have a 
buffering effect on MPTP/MPP+-induced neurotoxicity. Given a guardian role of CIB1 in MPTP/MPP+-induced 
neurotoxicity, our findings may provide new insights into a potential therapeutic strategy for Parkinson’s disease.
Materials and Methods
Cell culture and DNA transfection. Human dopaminergic neuroblastoma SH-SY5Y cells were rou-
tinely maintained under a humidified atmosphere of 5% CO2 at 37 °C in DMEM (Invitrogen) supplemented 
with 10% FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml). Transfection of cells was performed with 
Lipofectamine2000 (Invitrogen) for SH-SY5Y cells or RNAiFect (Qiagen) for primary mesencephalic neuronal 
cells.
Primary mesencephalic neuronal cell culture. Primary cultures of ventral mesencephalic dopaminergic 
neurons were prepared from rat embryos at embryonic day 14 as described previously2219. In brief, the neurons 
were plated at 2.0 × 105 cells per 18 × 18 mm glass coverslip or 4.0 × 105 cells per well in six-well plates pre-coated 
with poly-D-lysine (50 µg/ml) and laminin (2 µg/ml). The cells were cultured under a humidified atmosphere 
of 5% CO2 at 37 °C in Neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen) and GlutaMax-1 
(Invitrogen).
Plasmids. A full-length human CIB1 cDNA was amplified by PCR from a HeLa Hybrid Hunter Premade 
cDNA Library (Invitrogen). To construct an expression vector encoding Flag epitope-tagged CIB1 (Flag-CIB1), 
we amplified CIB1 cDNA by PCR with the primers 5′-ACCAAGCTTATGGGGGGCTCGGGCAGT-3′ 
(HindIII site underlined) and 5′-ACCGCGGCCGCTCACAGGACAATCTTAAA-3′ (NotI site underlined). 
The resulting PCR product was digested with HindIII and NotI and inserted into the corresponding sites of the 
p3xFLAG-CMV-10 vector (Sigma). For bacterial expression of a GST fusion protein of CIB1, CIB1 cDNA was 
amplified by PCR and cloned into the pGEX4 T vector (Amersham Biosciences). cDNAs for the ASK1 mutants 
ASK1(1–377), ASK1(378–648), ASK1(649–938), and ASK1(939–1374) were amplified by PCR and cloned into 
the pET28a vector (Novagen). Mammalian expression vectors encoding HA-ASK1, Myc-ASK1, Myc-JNK1, 
HA-MKK7, and HA-Trx1were previously described22,51.
RNA interference. The target sequence [sense 5′-AAAGACAGCCTTAGCTTTGAG-3′] for human 
CIB1 RNAi was selected with the use of the siRNA target finder program of Ambion. The annealed oli-
gonucleotides including sense and anti-sense strands of the target sequence were inserted into the pSUPER.
retro vector (OligoEngine). As a control, annealed oligonucleotides containing a target sequence (sense 
5′-GGCTACGTCCAGGAGCGCACC-3′) for a GFP shRNA were inserted into the same vector. The nucleo-
tide sequences of the various inserts were confirmed by DNA sequencing. SH-SY5Y cells were transfected with 
pSUPER.retro vectors encoding either the control (GFP) or CIB1 shRNA, and stable transfectants were selected 
in the presence of puromycin (0.25 μg/ml). Rat CIB1 siRNA (sense 5′-AAGAGTCACTGCATACCCGAG-3′), 
Mouse ASK1 siRNA (sense 5′-AATTGCAGTCTGCACAGCCTTTCGG-3′), or control GFP siRNA (sense 
5′-GGCTACGTCCAGGAGCGCACC-3′) oligonucleotides were obtained from Invitrogen and introduced into 
primary rat mesencephalic dopaminergic neurons by transfection for 48 h with the use of RNAiFect (Qiagen).
Antibodies. Mouse monoclonal antibodies to hemagglutinin (HA) epitope or to Flag epitope were purchased 
from Roche or Sigma, respectively. Mouse monoclonal antibodies to Myc epitope and rabbit polyclonal antibod-
ies to the Thr845-phosphorylated form of human ASK1 were obtained from Cell Signaling Technology. Rabbit 
polyclonal antibodies to ASK1, TRAF2, and MKK7 were from Santa Cruz Biotechnology. Mouse monoclonal 
antibodies to JNK1 were obtained from BD Bioscience Pharmingen. Rabbit polyclonal antibodies to tyrosine 
hydroxylase (TH) were from Chemicon. A polyclonal antibody to CIB1 was generated in rabbits injected with a 
GST-CIB1 fusion protein.
Immune complex kinase assays. Immune complex kinase assays were performed as previously 
described52,53. Briefly, cells were lysed in buffer A (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 12 mM β-glycerophosphate, 5 mM EGTA, 2 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, 10 mM NaF, 1 mM dithiothreitol), and the soluble 
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fractions (equal amounts of protein) of the lysates obtained by microcentrifugation were subjected to immuno-
precipitation with appropriate antibodies. The resulting precipitates were incubated for 30 min at 30 °C in 15 μl of 
a kinase reaction buffer53 in the presence of 1 μCi of [γ-32P]ATP and 2 μg of indicated substrate protein. Bacterially 
expressed GST fusion proteins of MKK6(K82A) and c-Jun(1–79) were used as substrates for ASK1 and JNK, 
respectively. The reaction mixtures were subjected to SDS-PAGE, and the extent of phosphorylation of the sub-
strate proteins was analyzed with a Fuji BAS 2500 phosphoimager.
In vitro binding assay. GST-CIB1 expressed in Escherichia coli was purified with the use of 
glutathione-conjugated agarose beads (Sigma). ASK1 variants were translated in vitro in the presence of [35S]methio-
nine with the use of a TNT reticulocyte lysate system (Promega). The 35S-labled proteins were incubated at 4 °C for 
4 h in a binding buffer54 with GST-fused proteins immobilized on glutathione-agarose beads. The bound 35S-labeled 
proteins were eluted from the beads and analyzed by SDS-PAGE and with a Fuji BAS 2500 phosphoimager.
Immunoblot analysis. Soluble fractions of cell lysates were subjected to SDS-PAGE, and the separated 
proteins were transferred electronically to PVDF membrane. The membrane was blocked with 5% nonfat milk 
in washing buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20), incubated for 1 h at room tem-
perature with primary antibodies in washing buffer containing 1% nonfat milk, washed, and then incubated 
for 1 h at room temperature with appropriate secondary antibodies conjugated with horseradish peroxidase 
(Amersham Biosciences). Immune complexes were visualized with the use of enhanced chemiluminescence rea-
gents (Amersham Biosciences).
Co-immunoprecipitation analysis. Cells were lysed with buffer A, and the lysates were centrifuged 
at 12,000 × g for 20 min at 4 °C. The resulting supernatants were incubated at 4 °C first for 4 h with appropri-
ate antibodies and then for 1 h in the additional presence of protein G-coupled Sepharose beads (Amersham 
Biosciences). The resulting precipitates were subjected to SDS-PAGE followed by immunoblot analysis.
Apoptotic cell death. SH-SY5Y cells expressing either a control or CIB1 shRNA were incubated in the 
absence or presence of 3 mM MPP+ for 20 h. The cells were fixed with 4% formaldehyde and stained with TUNEL 
using the In Situ Cell Death TMR Red kit according to manufacturer’s instructions (Roche). TUNEL-positive cells 
were analyzed by flow cytometry.
Cytotoxicity assay for mesencephalic dopaminergic neurons. Primary mesencephalic neuronal cells 
plated on glass cover slips coated with poly-D-lysine and laminin were incubated in Neurobasal media supplemented 
with B27 and GlutaMax-1 for 24 h and then transfected for 48 h with either GFP control or rat CIB1 siRNA oligonucle-
otides. The neurons were incubated in the absence or presence of 200 μM MPP+ for 20 h. They were then fixed with 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked with a solution containing 10% normal horse 
serum and 0.1% Triton X-100. The cells were incubated at 4 °C overnight with rabbit anti-tyrosine hydroxylase (TH) 
antibody (1:500; Chemicon), and then for 1 h at room temperature with biotinylated secondary antibodies to rabbit 
IgG (1:500; Vector Laboratories). Immune complexes were detected with an avidin-biotin immunohistochemical kit 
(Vector Laboratories). For evaluation of cytotoxicity, the numbers of TH-positive cells were counted in 30 randomly 
selected fields. Neuronal viability was expressed as a percentage of the viability of untreated cells transfected with the 
control siRNA. Data are means ± SD of values from three independent experiments.
MPTP administration for Parkinson’s disease animal model. CIB1 knockout mice were 
described previously20. All animal procedures were approved by the Institutional Animal Care and Use 
Committee of Korea University, and all methods were carried out in accordance with relevant guidelines and 
regulations. Routine genotyping was performed on genomic DNA isolated from tail snips of mice with three 
primers to identify wild-type and null alleles: Primer 1, 5′-AAGACCATCCTGAATCATGC-3′; Primer 
2, 5′-AAGTTATGGCGCGCCATCGA-3′; and Primer 3, 5′-TCTTCAGTGACACAGCAAC-3′. Two- to 
three-month old wild-type (WT) and CIB1−/− mice were used for MPTP treatment. MPTP (Sigma) was admin-
istered intraperitoneally using a standard subchronic method. This method consists of injecting MPTP (30 mg/
kg) daily for 5 consecutive days and sacrificing at 14 days after the start of injections. Control mice received an 
equal volume of saline (0.9%).
Immunohistochemistry. For staining of tyrosine hydroxylase, animals were perfused with PBS and then 
with 4% paraformaldehyde, and the brains were post-fixed in the same fixative solution for 2 h. Brains were cry-
oprotected in 30% sucrose and sectioned serially (40 μm). Subsequent immunostaining was performed by the 
free-floating method. The sections were incubated with anti-tyrosine hydroxylase antibody (1:5000; Chemicon) 
overnight and then with biotinylated secondary antibodies to rabbit IgG (1:1000; Vector Laboratories) for 1 h at 
room temperature. Subsequently, immune complexes were detected with an avidin-biotin immunohistochemical 
kit (Vector Laboratories) and then mounted on gelatin-coated slides, and examined under 40X magnification 
with a bright-field microscope (Olympus). Tyrosine hydroxylase-labeled neurons were counted with a computer-
ized optical fractionator (Stereo Investigator software v.7; mbf Bioscience, Williston, VT, USA).
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